The unresponsiveness of multidrug resistant tumor cells to antineoplastic chemotherapy is often associated with reduced cellular drug accumulation accomplished by overexpressed transport molecules. Moreover, intracellular drug distribution in resistant cells appears to be remarkably different when compared to their wild type counterparts. In the present paper, we report observations on the intracellular accumulation and distribution of doxorubicin, an antitumoral agent widely employed in chemotherapy, in sensitive and resistant cultured tumor cells. The inherent fluorescence of doxorubicin allowed us to follow its fate in living cells by laser scanning confocal microscopy. This study included flow cytometric analysis of drug uptake and efflux and analysis of the presence of the well known drug transporter P-glycoprotein. Morphological, immunocytochemical and functional data evidentiated the Golgi apparatus as the preferential intracytoplasmic site of drug accumulation in resistant cells, capable of sequestering doxorubicin away from the nuclear target. Moreover, P-glycoprotein has been found located in the Golgi apparatus in drug induced resistant cells and in intrinsic resistant cells, such as melanoma cells. Thus, this organelle seems to play a pivotal role in the intracellular distribution of doxorubicin.
Introduction
Most of the chemotherapeutic compounds used in cancer treatment exert their cytotoxic action by multifactorial mechanisms which involve several subcellular targets. The identification of these targets can provide new understanding of cytotoxic action mechanisms and can suggest innovative strategies in anticancer chemotherapy. In fact, the neoplastic cell sensitivity to certain anticancer agents could be enhanced by modifying the subcellular targets and then the cell response to the treatment.
In this context, studies on the intracellular localization of antitumoral drugs in cancer cells may provide useful contributions. Moreover, multidrug resistant (MDR) cells are generally characterized by reduced cellular drug accumulation and different intracellular drug distribution compared with their parental sensitive counterpart. Thus, a detailed knowledge of the drug disposition in various cell types exhibiting different degrees of resistance may provide an insight into the mechanisms underlying multidrug resistance and suggest pharmacological strategies for its therapeutic circumvention.
To this aim, several methodologies have been developed and applied in order to study subcellular drug localization with improved resolution. One approach is to separate the various cellular compartments and to measure the relative drug contents. This method, however, might introduce artifacts due to the possible dislocations of the drug molecules during the fractioning procedures. When the antitumoral agent is inherently fluorescent, such as anthracycline antibiotics, fluorescence microscopy, both conventional and confocal, can be usefully employed to study the drug subcellular localization (Coley et al., 1993; Meschini et al., 1994) . Confocal microscopy has several advantanges over conventional fluorescence microscopy, mainly in terms of elimination of out of focus epifluorescence and greater resolution (White et al., 1987; Wilson, 1990) . Secondary ion mass spectrometry (SIMS) microscopy has also been used to localize and quantify the 127 I of the iodinated anthracycline 4 -iododeoxyrubicin in cells from biopsies of patients treated with this drug (Fragu et al., 1992) . More recently, sophisticated electron microscopic methods have been employed to assess the presence or absence of a drug within clearly identifiable cellular organelles in order to locate precisely where it accumulates. In particular, electron energy-loss spectroscopy (EELS) and electron spectroscopic imaging (ESI) have been applied to assess the location of iodine-containing antitumoral drugs with electron microscopic resolution (Huxham et al., 1992; Diociaiuti et al., 1997) .
In the present paper we report observations, mainly performed by cytometric, morphological and ultrastructural methods, on the intracellular accumulation and distribution of anthracyclines in different cell lines, both sensitive and with different degrees of intrinsic or acquired resistance. The expression of the well known drug resistance marker P-glycoprotein (Pgp) has also been investigated in an attempt to clarify the influence of this transport protein on subcellular drug distribution and, thus, on cell sensitivity to the cytotoxic compounds.
Materials and Methods

Cells
Red blood cells were obtained from healthy donors as described elsewhere (Arancia et al., 1988) . After treatment with 100 µM doxorubicin (DOX) (Adriblastina, Pharmacia, Milan, Italy), erythrocytes were processed for freeze-fracture electron microscopy, as previously described (Arancia et al., 1988) .
The parental drug-sensitive human breast cancer MCF-7 cell line (MCF-7 WT) and its derivative MDR variant (MCF-7 DX) were kindly provided by Dr. K. Cowan from NCI, Bethesda, Maryland, USA. These cells were grown as monolayers in RPMI 1640 medium (Flow Laboratories, Irvine, Scotland) supplemented with 10% fetal calf serum, 1% L-glutamine and 0.1% gentamicin at 37 • C in a 5% CO 2 humidified atmosphere in air. MCF-7 DX cells were grown in complete medium containing 10 µM DOX.
Established human melanoma cell lines (M14, H14, JR8) were grown in RPMI 1640 medium supplemented with 1% non essential aminoacids, 1% L-glutamine, 100 IU mL −1 penicillin, 100 IU mL −1 streptomycin and 10% fetal calf serum at 37 • C in a 5% CO 2 humidified atmosphere in air.
The parental drug-sensitive human colon carcinoma LoVo cell line was grown in Ham's F12 medium (Flow Laboratories) supplemented with 10% fetal calf serum, 1% L-glutamine and vitamins at 37 • C in a 5% CO 2 humidified atmosphere in air.
Human breast carcinoma cells (CG5) were cultured at 37 • C in Dulbecco's modified Eagle's medium (DMEM), supplemented with 1% non essential amino-acids, 1% L-glutamine, 100 IU mL −1 penicillin, 100 IU mL −1 streptomycin and 10% fetal calf serum.
Cytoskeleton immunolabelling
For the detection of microtubules and actin filaments, cells grown on coverslips were fixed with 3.7% formaldehyde in phosphate buffer solution (PBS), pH 7.4, for 10 min at room temperature. After being washed in the same buffer, the cells were permeabilized with 0.5% Triton X-100 (Sigma Chemicals, St. Louis, MO) in PBS for 10 min at room temperature.
For actin detection, cells were stained with fluorescein-phalloidin (Sigma Chemicals) at 37 • C for 30 min.
For tubulin labelling, cells were incubated with anti-tubulin (α+β) monoclonal antibody (Amersham International plc, Little Chalfont, U.K.) at 37 • C for 30 min. After washing in phosphate buffer, incubation with a rhodamine-linked sheep anti-mouse IgG (Amersham International plc) at 37 • C for 30 min was performed.
Cytotoxicity studies
The clonogenic survival test was used to determine the cell sensitivity to DOX, DOX plus verapamil or DOX plus cyclosporin A. 700 cells were plated in tissue culture dishes (60 mm) and allowed to attach for 48 h before treatment with 1.7 µM (1 µg mL −1 ) DOX (Pharmacia) for 1 h in the presence or in the absence of 10 µM verapamil (Sigma Chemicals) or 5 µM cyclosporin A (Sigma Chemicals). After 8 days of incubation, cell colonies were fixed with 95 • ethanol for 15 min and stained with a solution of methylene blue in 80% ethanol for 1 h. Only colonies composed of more than 50 cells were evaluated. The surviving fraction was calculated by dividing the absolute survival of treated cells by the absolute survival of control cells. 
Anti-Pgp MAb
MAb MM4.17 which recognizes a human-specific epitope on the extracellular domain of the MDR1-P-glycoprotein isoform, was used in this study. Its optimal concentration for flow-cytometry and immunocytochemistry studies was 50 µg mL −1 .
Flow cytometry
All flow cytometric analyses were carried out on cell suspensions (10 6 cells mL −1 ) obtained by incubating cell cultures with EDTA and trypsin solutions.
For determination of cell surface P-glycoprotein, the cells were incubated for 30 min at 4 • C with MAb MM4.17 (50 µg mL −1 ). After washing with ice-cold PBS containing 10 mM NaN 3 , 1% bovine serum albumine (BSA; Sigma Chemicals) and 0.002% EDTA, cells were incubated for 30 min at 4 • C with F(ab ) 2 fragment of goat anti-mouse IgG fluoresceinconjugate (Sigma Chemicals) at a working dilution of 1:50. After washing, cells were immediately analyzed.
To detect intracellular expression of P-glycoprotein, cell suspensions were fixed with 2% paraformaldehyde in PBS for 10 min at 4 • C. Then the samples were permeabilized by adding 0.05% Triton X-100 for 10 min at 4 • C. The incubations with primary antibody (MAb MM4.17) and secondary antibody (F(ab ) 2 fragment of goat anti-mouse IgG fluorescein-conjugate) were performed for 30 min at 4 • C. For both surface and intracellular Pgp labelling experiments, negative controls were obtained by incubating the samples with mouse IgG2a isotypic globulins (Sigma Chemicals).
For drug accumulation studies, cell cultures were exposed to 1.7 µM DOX at 37 • C up to 30 h. For Pgp functionality studies, cells were preincubated with 10 µM verapamil or 5 µM cyclosporin A at 37 • C for 15 min. Then, 1.7 µM DOX was added to the cultures at 37 • C up to 30 h. At the various incubation times, cells were harvested, washed in ice-cold PBS and immediately analyzed.
For drug efflux studies, cell cultures were treated with 1.7 µM DOX for 4 h at 37 • C, washed with icecold PBS and then reincubated up to 30 h at 37 • C in drug-free medium, with or without modulators as described above. The samples were then processed for analysis of the drug content as in DOX accumulation experiments.
Fluorescence was analyzed with a FACScan flow cytometer (Becton Dickinson, Mountain View, CA) equipped with a 15 mW, 488 nm, air-cooled argon ion laser. The fluorescence emissions of fluorescein and doxorubicin were collected through 530 and 575 nm band-pass filters, respectively, and acquired in log mode. For DOX accumulation and efflux studies, drug fluorescence intensity was expressed as the mean channel and plotted versus time.
Fluorescence microscopy
To detect cell surface P-glycoprotein expression, cells grown on coverslips were incubated with MAb MM4.17 (50 µg mL −1 ) at 4 • C for 30 min. After washing in phosphate buffer, cells were incubated with goat anti-mouse IgG fluorescein-linked antibody (IgG-FITC; working dilution 1:20; Sigma Chemicals) at 4 • C for 30 min.
To detect intracellular expression of P-glycoprotein, cells were fixed with freshly prepared 3.7% formaldehyde in PBS for 10 min at room temperature. After washing in the same buffer containing 2% BSA, cells were permeabilized with 0.5% Triton X-100 in PBS for 5 min and then incubated with specific MAbs at 37 • C for 30 min. After several washes in PBS, cells were incubated again for 30 min with goat anti-mouse IgG-FITC, at a working dilution of 1:20. Mouse IgG2a isotypic globulins (Sigma Chemicals) were used in negative control samples. For Golgi apparatus staining, the method by Coan et al. (1993) was used. Briefly, after three washes in PBS, the cells were fixed and permeabilized with methanol at -20 • C for 10 min and then incubated with 50 mg mL −1 in PBS of wheat germ agglutininfluorescein linked (WGA-FITC; Sigma Chemicals) for 30 min at room temperature.
For the double-labelling of Golgi apparatus and Pglycoprotein, the cells were first labelled for the Golgi apparatus, following the method described above. After washing with PBS, the cells were incubated with MAb MM4.17 for 30 min at room temperature and, following several washes in PBS, incubated with a rhodamine-linked goat anti-mouse IgG (Sigma Chemicals) (working dilution 1:30). After washing, cover- Figure 9 . LSCM of intracellular DOX distribution in MCF-7 DX cells in the absence (a) and in the presence (b) of verapamil. This MDR reverting agent was able to inhibit the efflux of the drug. In fact, when DOX treatment was performed in association with verapamil (b), a stronger cytoplasmic signal was detected when compared to administration of DOX alone (a).
slips were mounted with glycerol-PBS (1:2) containing 2.5 mg mL −1 propyl gallate.
The observations were performed with a Nikon Microphot-SA fluorescence microscope (Nikon, Tokjo, Japan).
Confocal microscopy
The analysis of the intracellular distribution of DOX was carried out on living cells, grown on coverslips and mounted on glass microscope slides, in the presence of the culture medium. Cells were incubated with 1.7 µM DOX at 37 • C for incubation times ranging from 5 min to 30 h.
In order to avoid cell damage, the image acquisitions, recorded as section series, were made quickly on several cells present on different coverslips for each sample, acquiring signals from one field per coverslip. The observations were carried out using a Molecular Dynamics Sarastro 2000 laser scanning confocal microscope (Molecular Dynamics, Sunnyvale, CA). The excitation and emission wavelengths employed were 488 and 510 nm, respectively. The acquisition parameters were: objective 60x/1.40, image size of 1024×1024 pixels, pixel size of 0.17 µm, step size of 1.1 µm. To show both surface and internal cell structures, the section series were processed by lookthrough projection method. Voxel intensities along projection rays were summed: the rays lay perpendicular to the plane of the monitor screen. This method is also termed 'extended focus' because the resulting images appear to have gathered from a transparent specimen by a lens with large depth of focus. The acquisitions were recorded employing the pseudo-color intensity representation.
EELS imaging
Electron Energy Loss Spectroscopy (EELS), performed in a classical TEM environment, is a nondestructive spectroscopic technique for the characterization of the chemical properties of different samples. EELS uses the information carried by the transmitted electrons at the exit surface of the specimen. The scattering events suffered by the outgoing electrons are recorded. By evaluating the energy loss of electrons an EELS spectrum can be obtained which gives information about the chemical composition or electronic binding energies. Moreover, images can be obtained by collecting only electrons that suffered energy loss characteristic of an atomic species. This technique, namely Electron Spectroscopic Imaging, is able to obtain elemental maps with a resolution comparable to TEM resolution.
EELS imaging was performed on both sensitive and resistant MCF-7 cells, treated with 4 -deoxy-4 -iododoxorubicin (IDX), fixed with 2.5% glutaraldehyde and embedded by classical procedure. Unstained ultrathin sections were analyzed by a dedicated Zeiss EM902 transmission electron microscope (Diociaiuti et al., 1997) . The three-windows procedure was used in the iodine analysis. Energy windows of 540-580, 560-600 and 640-680 eV, respectively, were used. Reference images with high contrast were acquired by energy filtering at about 250 eV. Iodine map was colored in black and superimposed on the reference image.
Results and Discussion
Subcellular targets of anthracyclines
Most of the studies on the intracellular accumulation and distribution of antitumoral drugs in cancer cells have been performed using anthracyclines, a well known class of cytotoxic compounds widely employed in anticancer chemotherapy. Such studies are facilitated by the high inherent fluorescence of the anthracycline molecules, in that their presence in cellular material can be easily detected and visualized by fluorimetric methods, such as flow cytometry and fluorescence microscopy.
The antitumoral activity of anthracyclines has been attributed mainly to their intercalation between the base pairs of the DNA molecule which can alter the conformation of the nucleic acid, cause DNA fragmentation and induce inhibition of RNA and DNA synthesis (Mizuno et al., 1975; Monparler et al., 1976; Fritzsche et al., 1982; Ralph et al., 1983) . However, several studies showed that anthracyclineinduced cytotoxicity could be ascribed not only to an effect of the drug on nucleic acids but also on other important cellular structures, such as membranes and cytoskeleton.
As far as cellular membranes are concerned, it has been demonstrated that doxorubicin (DOX, also called adriamycin), the main congener of the anthracycline family, exhibits a specific affinity to negatively charged phospholipids (Duarte-Karim et al., 1976; Goormaghtigh and Ruysschaert, 1984; Henry et al., 1985) . Therefore, the lipid composition of the membrane seems to be important for the sensitivity of tumor cells to DOX and for this reason efforts have been directed towards modifying the plasma membrane in order to modulate the interaction with the drug and, subsequently, its cytotoxic action (Guffy et al., 1984) . Modifications of the cell surface induced by DOX, such as changes in the membrane fluidity, lipid composition, expression of membrane-bound enzymes as well as other cell surface functional properties, have been widely demonstrated (Tritton and Yee, 1982; Siegfried et al., 1983; Oth et al., 1987) . In our previous investigations performed by ultrastructural and spectroscopic methods on the anthracyclinemembrane interaction, we found that the incorporation of DOX molecules within both lipid layers induces remarkable changes in some ultrastructural and physical parameters of the plasma membrane with consequent alterations in the functional properties (Arancia et al., 1988; Diociaiuti et al., 1991a; Diociaiuti et al., 1991b; Arancia et al., 1994; Arancia et al., 1995) .
In particular, freeze-fracture electron microscopy revealed a very unusual distribution of protein intramembrane particles in membranes of human erythrocytes treated with DOX when compared to the control ones (Figure 1a) . Numerous smooth areas of variable geometry were detectable on a large part of the protoplasmic fracture face of treated erythrocytes (Figure 1b) . A number of evidences supported the hypothesis that the smooth areas might represent a vi-sualization of the DOX molecules incorporated inside the lipid bilayer (Arancia et al., 1995) .
Concerning the cytoskeleton, several studies showed that the anthracycline-induced cardiotoxicity could be ascribed to an effect of the drug on the cytoskeletal apparatus of cardiac cells (Lewis and Gonzales, 1986; Rabkin and Sunga, 1987) . We found that both doxorubicin and daunomycin (DAU) induced multinucleation and spreading phenomena in cultured cells, interferring with the organization of microtubules and microfilaments (Molinari et al., 1990) . In particular, it was observed that DAU was able to modulate the microtubule reassembly in human melanoma cells treated with colcemid and that treatment with DAU induced the stabilization of the microtubules, making them more resistant to the action of antimicrotubular agents (Molinari et al., 1991) . Figure 2 shows the actin and tubulin arrangements (a and c, respectively) in control CG5 cells and the relative modifications induced by the exposure to 50 µM DOX for 2 h (b and d, respectively).
These observations seem to confirm the cytoskeletal apparatus as another important target involved in the mechanism of action of anthracyclines.
Intracellular accumulation and distribution of DOX in wild type sensitive breast carcinoma cells and in their derivative MDR variants
Cells expressing the MDR phenotype can be selected in vitro by prolonged exposure to various antitumoral drugs. The acquisition of MDR is often associated with changes in both intracellular drug content and disposition (Fojo et al., 1985; Willingham et al., 1986; Schurrhuis et al., 1991; Coley et al., 1993) . These changes appear to be mediated by different protein transporters which are generally overexpressed in MDR cells.
We have compared the subcellular localization of anthracycline molecules in wild type human breast cancer cells (MCF-7 WT) and in their derivative MDR variants (MCF-7 DX). Moreover, the relationship between expression of the well-known drug resistance marker P-glycoprotein (Pgp) and drug distribution in this cell model has been investigated.
As expected, flow cytometric analysis of DOX accumulation revealed that in MCF-7 WT cells the fluorescence intensity due to the intracellular drug content was much higher than in MCF-7 DX cells (Figure 3a ). Besides this difference in intracellular drug accumulation, wild type and resistant cells were found to be remarkably different in the distribution of Figure 12 . Sensitivity to DOX of H14 and LoVo cells in the absence and in the presence of cyclosporin A (CsA). H14 cells treated with DOX alone showed a survival fraction significantly higher than that of LoVo cells. CsA induced a reduction in cell survival in melanoma cells and no effect in LoVo cells. the anthracycline compound. When sensitive MCF-7 WT cells were treated with 1.7 µM DOX for 1 h and observed under living conditions by laser scanning confocal microscopy (LSCM), the fluorescent drug molecules localized preferentially in the nuclei (Figure 3b) . In MCF-7 DX cells DOX appeared to be exclusively located within the cytoplasm, while the nuclei were completely negative (Figure 3c ).
Changes in intracellular drug localization, and in particular decrease in the nuclear/cytoplasmic ratio of doxorubicin fluorescence, were detected in several resistant cell lines (Broxterman et al., 1990; De Lange et al., 1992) . The shift in the ratio nuclear drug/cytoplasmic drug has been reported to be related to resistance to doxorubicin (2.8-3.6 in sensitive cells vs. 0.1-0.4 in cells with 70-fold higher level of resistance) (Schurrhuis et al., 1993) . Biophysical studies (Frezard and Garnier-Suillerot, 1991) demonstrated that the intercalation between the base pairs of DNA induced the partial quenching of DOX fluorescence. However, drug molecules bound to the negatively charged phosphate of DNA, but not intercalated, gave out a fluorescent signal. According to these studies, high levels of free or phosphate bound DOX are present in the nuclei of parental sensitive cells which appear to be intensely fluorescent. The concentration of the drug in three nuclear states (free, intercalated and phosphate-bound) will reflect a passive equilibrium within the nucleus. Consequently, if significant levels of DOX were intercalated into the DNA of resistant cells, the proportionally high levels of free and phosphate-bound drug should also be detected and an appropriate fluorescent signal should be observed. Thus, the absence of signal from the nuclei of the drug-resistant cells very strongly suggests that they contain negligible levels of DOX.
The preferential location of the anthracycline molecules within the nuclei of sensitive cells and their absence, or at least very low concentration, in the nuclei of MDR cells were also confirmed by electron energy loss spectroscopy (EELS) imaging (Diociaiuti et al., 1997) . This method was applied on ultrathin sections of both wild type and resistant MCF-7 cells treated with 4 -deoxy-4 -iododoxorubicin (IDX), an halogenated derivative of DOX, taking advantage of the presence of the iodine atom in this molecule. Figure 4a shows the iodine mapping (black signal), superimposed on the respective reference image, in a representative sensitive MCF-7 cell. The preferential localization of IDX inside the nucleus was well evident. Moreover, the colocalization of the I signals and the chromatine clumps confirmed the intercalation of IDX between the base pair of the nucleic acids . The I signal was never detected in resistant cells treated with the same IDX dose, as shown in Figure 4b .
The time courses of drug uptake and the subsequent drug efflux performed by flow cytometry on both MCF-7 WT and MCF-7 DX cells revealed remarkable difference in the accumulation capability of DOX in the two cell types ( Figure 5 ). When sensitive cells were exposed to 1.7 µM DOX, the fluorescence intensity increased rapidly. Conversely, a very low increase in fluorescence could be detected in resistant cells, revealing a noticeable reduction in drug uptake and/or the existence of potent mechanisms of drug efflux. After 3 h of DOX exposure the intensity of fluorescence emitted by the molecules of the antitumoral drug present inside sensitive cells was about eight time higher than the intensity from the resistant counterparts. When DOX-treated cells were allowed to recover in drug free medium, the fluorescent signal in MCF-7 DX cells after 1h recovery was approximately the same as the negative control, indicating a complete drug efflux, whereas in wild type MCF-7 cells a low reduction (about 30%) was revealed after recovery for 4 h.
Besides differences in intracellular drug concentration, sensitive and resistant cells showed a different pattern of drug localization during the early phases of DOX uptake, as revealed by LSCM. In MCF-7 WT cells, observed after 15 min of drug exposure, DOX was localized preferentially in cytoplasmic vesicles in the perinuclear area and a weak positivity was visible inside the nuclei (Figure 6a ). After the same period of treatment, the nucleus of the MCF-7 DX cells was completely negative with faint fluorescence visible in the cytoplasm (Figure 6b ). At 30 min of treatment, the nuclei of sensitive cells displayed a strong positivity and a clear visible fluorescent signal could also be detected in the perinuclear area (Figure 6c) . In resistant cells, a weak cytoplasmic signal was observed after 30 min of DOX exposure whereas the nuclei were still negative (Figure 6d) .
The different subcellular localization of DOX observed in parental and resistant MCF-7 cells is in good agreement with previous reports which described a very similar anthracycline distribution in a number of cell pairs. A vesicular perinuclear localization of the drug, described as 'punctate pattern' in LSCM studies, has been reported in several drug resistant cells (Sehested et al., 1987; Beck et al., 1989; Keizer et al., 1989; Gervasoni et al., 1991) . Therefore, the transport of the drug by acidic vesicles seems to represent an important aspect of the multidrug resistance phenomenon (Sehested et al., 1987) . The sequestration of the drug molecules into the intracytoplasmic vesicles can be mediated by transport associated proteins, such as Pgp (Willingham et al., 1987; Molinari et al., 1994) and MRP (multidrug resistance protein) (Breuningher et al., 1995) , located on the membrane of the cytoplasmic organelles. These transport proteins determine abnormal subcellular compartmentation of anthracyclines, preventing their interaction with the intracellular targets (Gervasoni et al., 1991; Boiocchi and Toffoli 1992; Schurrhuis et al., 1993) . In particular, the removal of the drug from the nucleus in resistant cells may prevent the interaction of the putative cell targets, such as DNA, with the cytotoxic drug (Gervasoni et al., 1991; Seidel et al., 1995) . Notwithstanding, the intracellular compartmentation of anthracyclines could also depend on their lipophilic characteristics or their specific structural properties (Lothstein et al., 1992; Duffy et al., 1996; Toffoli et al., 1996) .
Immunocytochemical localization of Pgp in breast carcinoma cells
In order to verify the possible involvement of Pgp in the regulation of drug distribution, the surface and intracellular expression of the drug transporter has been studied using the monoclonal antibody MM4.17 . MAb MM4.17 recognizes a defined, human-specific epitope on the P-glycoprotein extracellular domain .
Flow cytometric determination of cell surface Pgp (Figure 7a) showed that MDR variants of MCF-7 cells were positive for MAb MM4.17, which reacted with virtually all the resistant cells, and the fluorescence signal was 2-logs different from control sample. As expected, MCF-7 WT cells did not show any reactivity: in fact, the fluorescence profile of MM4.17-labelled sensitive cells and that of negative control cells were indistinguishable.
Immunofluorescence microscopy observations confirmed the data obtained by flow cytometric analysis. MAb MM4.17 recognized epitopes on the surface of MCF-7 DX cells (Figure 7b ) whereas the sensitive parental cells appeared to be completely negative when labelled with the same antibody (Figure 7c) .
Then, we examined Pgp intracellular localization on fixed and permeabilized cells: a strong fluorescent signal was observed both in the perinuclear region and on the plasma membrane of MCF-7 DX cells. This suggested that in MDR cells Pgp could be also located in a cytoplasmic region likely to be occupied by the Golgi apparatus . In order to confirm such a location of Pgp, MCF-7 DX cells were double stained with fluorescein-linked wheat germ agglutinin (WGA) and with MAb MM4.17 followed by rhodamine-linked goat anti-mouse IgG. The double immunofluorescence labelling showed that fluorescein ( Figure 8a , Golgi apparatus) and rhodamine (Figure 8b , Pgp) signals were superimposed upon one another in the same perinuclear region. The GolgiPgp colocalization was also observed in other MDR cell lines, thus indicating that the location of the drug transporter in the Golgi apparatus was not a feature specific to a single cell type.
Taken all together, these observations were suggestive of an important role played by the Golgi compartment in the intracellular transport of anthracycline molecules and indicated that intracytoplasmic Pgp might have a functional role.
To verify these hypotheses, the intracellular localization of DOX in MCF-7 DX cells treated with DOX alone or in the presence of verapamil, a reversing agent that binds to the transporter with high affinity Safa et al., 1987) was studied using LSCM. Resistant cells treated with DOX were able to promptly extrude the drug, showing a very low fluorescent signal after 1h efflux (Figure 9a ). Conversely, when DOX treatment was performed in association with verapamil, a strong signal was detected in the cytoplasm, mainly in the perinuclear region corresponding to the Golgi apparatus (Figure 9b ).
Our observations, in particular the significant expression of Pgp in the Golgi apparatus where DOX preferentially accumulates , and those reported by others (Rutherford and Willingham, 1993 ), seem to demonstrate that Pgp is present on the membrane of the Golgi elements and that it can also actively function in this region as drug transporter.
In addition, it has been reported that Pgp is highly represented not only on the plasma membrane and in the cytoplasm but also in the nuclear envelope and inside the nucleus of MDR cells (Baldini et al., 1995) . Therefore, the nucleus seems to be another important site for Pgp activity in the regulation of the intracellular DOX distribution in resistant cells. In particular, nuclear Pgp is involved in the active removal of cytotoxic drugs from their intranuclear targets.
In conclusion, the different subcellular accumulation and distribution of DOX in sensitive and resistant cells seem to be the result of combined transport activities exerted by Pgp located in various subcellular compartments of MDR cells.
Intracellular distribution of Pgp and DOX in melanoma cells
Malignant melanoma in its metastatic stage is highly unresponsive to chemotherapy (Koh, 1991) . The involvement of transport-associated proteins such as MRP (multidrug resistance related protein) (Zaman et al., 1993) , LRP (lung resistance protein) (Scheper et al., 1993) and the well known multidrug resistance marker Pgp has been investigated (Schadendorf et al., 1995) . However, the mechanisms underlying intrinsic-MDR of malignant melanoma are yet to be elucidated.
In our recent study (Molinari et al., 1998 ) the presence of Pgp was demonstrated in the cytoplasm of human melanoma cell lines which do not express this transport molecule on the cell surface.
The intracellular expression and localization of Pgp were analyzed on fixed and permeabilized cells by flow cytometry and fluorescence microscopy using MAb MM4.17. Flow cytometric analysis showed that this monoclonal antibody reacted with intracellular epitopes in all three human melanoma cell lines examined (M14, H14, JR8) (Figure 10a ). The fluorescence microscopy observations suggested that Pgp could be located in the Golgi apparatus of human melanoma cells. Double-staining experiments, performed with MAb MM4.17 followed by rhodamine-linked goat anti-mouse IgG and fluorescein-linked WGA confirmed this hypothesis. The double immunofluorescence labelling showed that rhodamine (Figure 10b , Pgp) and fluorescein ( Figure 10c , Golgi apparatus) signals were strikingly coincident in the same perinuclear region.
To investigate if Pgp detected in the Golgi apparatus plays a role in drug transport, the intracellular localization of DOX was investigated by LSCM. M14 cells were exposed to 1.7 µM DOX and observed under living conditions at different time intervals (Figure 11) . During the first minutes of treatment, the early phase of the drug uptake could be depicted. At 15 min the drug was mainly located in the Golgi apparatus, whereas a weak fluorescence was visible in the nucleus (Figure 11a) . In M14 cells treated with DOX for 1 h (Figure 11b ) all the nuclei were strongly fluorescent: in most of the cells the drug was concentrated in well defined plasma membrane zones and a residual fluorescence positivity was still visible in perinuclear regions. When DOX treated cells were allowed to recover in drug-free medium, a slow drug efflux occurred. After about 24 h the nuclei appeared to be scarcely positive (Figure 11c ). Under this last experimental condition, the intracellular drug distribution was comparable to that observed at the beginning of DOX administration; in fact, in both cases, the drug appeared to be located almost exclusively in the cytoplasm, close to the nucleus.This finding suggests that when DOX concentration is low, the drug molecules are preferentially accumulated in the acidic vesicular structures of the Golgi apparatus, where Pgp epitopes were principally found.
We previously interpreted ) the preferential location of DOX in the perinuclear region of M14 cells, observed during both the initial period of the drug uptake and the efflux phase, to be due to the DOX molecules being weak bases. Following the diffusion across the porous nuclear envelope DOX molecules, due to their positive electric charge, localized in acidic vesicles of the trans Golgi elements (Rutherford and Willingham, 1993 ) that bind and are transported along microtubules towards the cell surface (Peterson and Trouet, 1978; Hindenburg et al., 1989) .
In the light of the results herein reported, the involvement of Pgp localized in the Golgi apparatus in the sequestration of the drug molecules inside the lumen of vesicles has to be considered.
Thus, the effect of two well known MDR modifiers, verapamil and cyclosporin A (Safa et al., 1987; Saeki et al., 1993) on the intracellular distribution of DOX in melanoma cells has been studied. As observed by LSCM, in cells recovered for 24 h in drug-free medium (Figure 11c ) DOX was located preferentially in the Golgi region whereas in the presence of cyclosporin A, DOX was mainly retained into the nucleus (Figure 11d ). Such a difference confirms the roles of sequestration, transport and extrusion played by Pgp located on the membranes of Golgi vesicles. In fact, during the efflux in the absence of the MDR modifier, the scarce intranuclear localization of DOX can be attributed to drug concentration gradients between cell compartments, which prevent nuclear accumulation through a reduction in cytoplasmic concentration . When the efflux occurs in the presence of cyclosporin A, the Pgp function is inhibited resulting in a significant intranuclear drug retaining.
Moreover, both verapamil and cyclosporin A were able to sensitize melanoma cells to DOX. Figure 12 shows the percent cell survival of H14 melanoma cells after treatment with 1.7 µM DOX or DOX plus cyclosporin A. These values are compared with those obtained on wild type colon carcinoma cells (LoVo) under the same treatment conditions. After treatment with DOX alone, H14 cells showed a survival fraction significantly higher than that of LoVo cells, confirming the intrinsic resistance of the melanoma cells to the cytotoxic effect of the anthracycline compound. When DOX treatment was performed in association with cyclosporin A, a reduction in cell survival was detected in melanoma cells whereas, as expected, no effect of the MDR modulator could be observed in LoVo cells.
In conclusion, Pgp located in the Golgi apparatus, either in drug induced-MDR cells or in intrinsic drug resistant cells, such as melanoma cells, seems to exert a transport activity, as supported by the effects of MDR-modifiers. Thus, the hypothesis that Pgp in the Golgi apparatus represents, if not a decisive, a complementary protective mechanism against toxic agents in chemotherapy-refractory malignant melanoma, seems to be supported.
